UBS AM
NWBO

UBS AM’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

UBS AM’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-26,700
Closed -$39K – 2688
2016
Q1 		$39K Hold
26,700
– – ﹤0.01% 2619
2015
Q4 		$85K Hold
26,700
– – ﹤0.01% 2667
2015
Q3 		$167K Buy
26,700
+2,600
+11% +$24.3K ﹤0.01% 2534
2015
Q2 		$239K Buy
+24,100
New +$211K ﹤0.01% 2501

Other funds holding NWBO

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS AM's NWBO Position: Q2 2016 in Review

UBS AM sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q2 2016, closing a stake of 26,700 shares — an estimated $39K sold.

UBS AM first reported a position in NWBO in Q2 2015 and held it in 4 quarters. The position peaked at $239K in Q2 2015. 64 funds tracked by Wall St. Rank hold NWBO as of Q2 2016.

  • UBS AM reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q2 2016 after selling out during the quarter.
  • UBS AM sold 26,700 Northwest Biotherapeutics, Inc. Common stock shares in Q2 2016, an estimated $39K.
  • UBS AM first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2015 and held it in 4 quarters.
  • UBS AM's Northwest Biotherapeutics, Inc. Common stock position peaked at $239K in Q2 2015.
  • 64 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q2 2016.

Based on UBS AM's 13F filing for Q2 2016, filed 9 Aug 2016.